Patient and provider preferences for long-acting TB preventive therapy
IJTLD Open · 2025-05 · 2 (5) · 276-283
DOI: 10.5588/ijtldopen.24.0670 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.05.2025. Verfasst von M Vermeulen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
BACKGROUND Tuberculosis preventive therapy (TPT) is critical for TB elimination but is underutilised. Long-acting (LA) TPT can potentially improve linkage to care, treatment adherence and outcomes. METHODS We conducted a cross-sectional in-person survey in two high TB burden countries to evaluate preferences and concerns about LA formulations for TPT. The survey compared oral pills to LA injections, implants, and microarray patches (MAPs). A parallel online survey of healthcare providers (HCPs) in low- and middle-income countries (LMICs) assessed the perceived feasibility of implementation. Data were summarised by descriptive statistics. RESULTS We recruited 409 patients (India, n = 209; South Africa, n = 200) and 94 HCP participants. The mean age of patients was 40 years; 65% were female, and 26% reported a history of TPT. Injectable LA-TPT was the most preferred modality, followed by pills, implants, and then MAPs. The majority (75%) expressed a strong willingness to try injectable LA-TPT. Among providers, 43% favoured injectable LA-TPT, 26% preferred oral pills, 18% implants, and 13% MAPs. Cost was a significant factor influencing HCPs’ willingness to adopt LA-TPT, while potential inefficacy and prolonged side effects were the highest concerns of patient respondents. CONCLUSION Injectable LA-TPT may be highly acceptable and feasible if concerns surrounding cost, effectiveness, and safety are addressed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
- College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
- College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
- College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
- Johns Hopkins India, Center for Infectious Diseases in India (CIDI), Pune, India.
- Johns Hopkins Bloomberg School of Public Health, Epidemiology, Baltimore, MD, USA.
Förderung
- NIAID NIH HHS
Zitieren
APA
Vermeulen, M., Scarsi, K. K., Furl, R., Sayles, H., Anderson, M. J., Valawalkar, S., Kadam, A., Cox, S. R., Mave, V., Barthwal, M., Schutz, C., Ward, A., Dountio Ofimboudem, J., Meintjes, G., Rannard, S., Owen, A., & Swindells, S. (2025). Patient and provider preferences for long-acting TB preventive therapy. IJTLD Open, 2(5), 276-283. https://doi.org/10.5588/ijtldopen.24.0670
Vancouver
Vermeulen M, Scarsi KK, Furl R, Sayles H, Anderson MJ, Valawalkar S, et al. Patient and provider preferences for long-acting TB preventive therapy. IJTLD Open. 2025;2(5):276-283. doi:10.5588/ijtldopen.24.0670
BibTeX
@article{Vermeulen2025,
author = {Vermeulen, M and Scarsi, K K and Furl, R and Sayles, H and Anderson, M J and Valawalkar, S and Kadam, A and Cox, S R and Mave, V and Barthwal, M and Schutz, C and Ward, A and Dountio Ofimboudem, J and Meintjes, G and Rannard, S and Owen, A and Swindells, S},
title = {Patient and provider preferences for long-acting TB preventive therapy},
journal = {IJTLD Open},
year = {2025},
volume = {2},
number = {5},
pages = {276--283},
doi = {10.5588/ijtldopen.24.0670}
}
EUVIMED